Blog
About

43
views
0
recommends
+1 Recommend
3 collections
    1
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Recovery from COVID-19 Pneumonia in a Patient with Acute Severe Colitis

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Introduction: The coronavirus disease 2019 (COVID-19) pandemic has increased concern regarding SARS-CoV-2 infection in inflammatory bowel disease (IBD) patients, especially those on immunosuppressive therapies or with active disease. There are limited reports describing the clinical features of COVID-19 in an IBD population, and the impact of immunosuppression on the severity of the infection remains unclear. Case Report: A 33-year-old female patient with a long history of ulcerative colitis, poorly controlled, was admitted with COVID-19 a few days after being discharged from the hospital for treatment of acute severe ulcerative colitis. High-risk factors for COVID-19 complications, i.e., high-dose steroids (40 mg prednisone) and severe active disease, were present at admission. Despite the development of extensive pulmonary involvement, the patient had a favorable outcome. Discussion: Management of IBD patients during the COVID-19 pandemic has been challenging. Measures to minimize the potential risk of SARS-CoV-2 infection, including strict social distancing and self-isolation, in the IBD population have been recommended, especially for high-risk patients. Although steroid tapering and persistence of biologics are advised by professional groups, the best treatment strategy for IBD patients presenting a flare during the outbreak has yet to be defined.

          Related collections

          Most cited references 3

          • Record: found
          • Abstract: found
          • Article: not found

          Management of IBD during the COVID-19 outbreak: resetting clinical priorities

          The coronavirus disease (COVID-19) worldwide outbreak has led to a dramatic challenge for all healthcare systems, including inflammatory bowel disease (IBD) centres. Here, we describe the fast changes and clinical issues that IBD specialists could face during this SARS-CoV-2 infection pandemic, highlighting the potential rearrangements of care and resetting of clinical priorities.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            A fatal case of COVID-19 pneumonia occurring in a patient with severe acute ulcerative colitis

              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              Relevant Infections in Inflammatory Bowel Disease, and Their Relationship With Immunosuppressive Therapy and Their Effects on Disease Mortality

                Bookmark

                Author and article information

                Journal
                IID
                IID
                10.1159/issn.2296-9365
                Inflammatory Intestinal Diseases
                S. Karger AG
                2296-9403
                2296-9365
                2020
                June 2020
                06 May 2020
                : 5
                : 2
                : 93-98
                Affiliations
                aDivision of Gastroenterology and Hepatology, Department of Gastroenterology, Hospital das Clínicas, School of Medicine, University of São Paulo, São Paulo, Brazil
                bDepartment of Gastroenterology, Hospital das Clínicas, School of Medicine, University of São Paulo, São Paulo, Brazil
                cInstituto da Criança e do Adolescente, Hospital das Clínicas, School of Medicine, University of São Paulo, São Paulo, Brazil
                dLaboratory of Clinical and Experimental Gastroenterology (LIM-07), Hospital das Clínicas, School of Medicine, University of São Paulo, São Paulo, Brazil
                Author notes
                *Karoline Soares Garcia, Division of Gastroenterology and Hepatology, Department of Gastroenterology, Hospital das Clínicas, School of Medicine, University of São Paulo, 255, Doutor Enéas de Carvalho Aguiar Ave., São Paulo, SP 05403000 (Brazil), karolinesoaresg@gmail.com
                Article
                508161 PMC7098314 Inflamm Intest Dis 2020;5:93–97
                10.1159/000508161
                PMC7098314
                32232049
                The Author(s). Published by S. Karger AG, Basel

                This article is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND). Usage and distribution for commercial purposes as well as any distribution of modified material requires written permission. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

                Page count
                Figures: 3, Pages: 5
                Categories
                Case Report

                Comments

                Comment on this article